Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults

Nephrology Dialysis Transplantation

Volumn 28, Issue 5, 2013, Pages 1225-1232

  Takei, Takashi ^a   Itabashi, Mitsuyo ^a   Moriyama, Takahito ^a   Kojima, Chiari ^a   Shiohira, Syunji ^a   Shimizu, Ari ^a   Tsuruta, Yuki ^a   Ochi, Ayami ^a   Amemiya, Nobuyuki ^a   Mochizuki, Toshio ^a   Uchida, Keiko ^a   Tsuchiya, Ken ^a   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

nephrotic syndrome; relapse; rituximab; steroid dependent minimal change

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG INFUSION; DRUG WITHDRAWAL; FEMALE; HICCUP; HUMAN; HUMORAL IMMUNE DEFICIENCY; LEUKOPENIA; MAINTENANCE DRUG DOSE; MALE; MINIMAL CHANGE NEPHROTIC SYNDROME; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; RELAPSE; REMISSION; SINGLE DRUG DOSE;

NEPHROTIC SYNDROME; RELAPSE; RITUXIMAB; STEROID DEPENDENT MINIMAL-CHANGE;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; MALE; NEPHROSIS, LIPOID; PREDNISOLONE; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION;

EID: 84877990621     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs515     Document Type: Article

References (25)

1. Takei T, Koike M, Suzuki K et al. The characteristics of relapse in adult-onset minimal-change nephrotic syndrome. Clin Exp Nephrol 2007; 11: 214-217
2. Eguchi A, Takei T, Yoshida T et al. Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome. Nephrol Dial Transplant 2010; 25: 124-129
3. Iijima K, Hamahira K, Tanaka R et al. Risk factors for cyclospor-ine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int 2002; 61: 1801-1805
4. Kranz B, Vester U, Büscher R et al. Cyclosporine-A-induced ne-phrotoxicity in children with minimal-change nephrotic syndrome: long-term treatment up to 10 years. Pediatr Nephrol 2008; 23: 581-586
5. Guigonis V, Dallocchio A, Baudouin V et al. Rituximab treatment for severe steroid-or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 2008; 23: 1269-1279
6. Kamei K, Ito S, Nozu K et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 2009; 24: 1321-1328
7. Hofstra JM, Deegens JK, Wetzels JF. Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome? Nephrol Dial Transplant 2007; 22: 2100-2102
8. François H, Daugas E, Bensman A et al. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. Am J Kidney Dis 2007; 49: 158-161
9. Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med 2007; 356: 2751-2752
10. Maloney DG, Grillo-López AJ, White CA et al. IDEC-C2B8 (RIT) anti-CD20 monoclonal antibody therapy in patients with relapsed low grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195
11. Wong CF. Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculities: what is the current evidence? Nephrol Dial Transplant 2007; 22: 32-36
12. Perosa F, Favoino E, Caragnano MA et al. CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev 2005; 4: 526-531
13. Goldberg SL, Pecora AL, Alter RS et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalo-virus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002; 99: 1486-1488
14. Goetz M, Atreya R, Ghalibafian M et al. Exacerbation of ulcera-tive colitis after rituximab salvage therapy. Inflamm Bowel Dis 2007; 13: 1365-1368
15. Lagrue G, Branellec A, Blanc C et al. A vascular permeability factor in lymphocyte culture supernants from patients with ne-phrotic syndrome. II. Pharmacological and physicochemical properties. Biomedicine 1975; 23: 73-75
16. Hardwicke J, Soothill JF, Squire JR et al. Nephrotic syndrome with pollen hypersensitivity. Lancet 1959; 1: 500-502
17. Lama G, Luong I, Tirino G et al. T-lymphocyte populations and cytokines in childhood nephrotic syndrome. Am J Kidney Dis 2002; 39: 958-965
18. Suranyi MG, Guasch A, Hall BM et al. Elevated levels of tumor necrosis factor-alpha in the nephrotic syndrome in humans. Am J Kidney Dis 1993; 21: 251-259
19. Yang T, Nast CC, Vo A et al. Rapid remission of steroid and mycophenolate mofetil (MMF)-resistant minimal change ne-phrotic syndrome after rituximab therapy. Nephrol Dial Transplant 2008; 23: 377-380
20. Peters HP, van de Kar NC, Wetzels JF. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature. Neth J Med 2008; 66: 408-415
21. Smith GC. Is there a role for rituximab in the treatment of idio-pathic childhood nephritic syndrome? Pediatr Nephrol 2007; 22: 893-898
22. Kurosu N, Sugiura H, Iwasaki C et al. Successful use of singledose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome. Intern Med 2009; 48: 1901-1904
23. Sawara Y, Itabashi M, Kojima C et al. Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome. Clin Nephrol 2009; 72: 69-72
24. Sugiura H, Takei T, Itabashi M et al. Effect of single-dose rituxi-mab on primary glomerular diseases. Nephron Clin Pract 2010; 117: c98-c105
25. Amemiya N, Takei T, Kojima C et al. Induction of remission following a single dose of rituximab alone in a patient with minimal change nephrotic syndrome. Clin Exp Nephrol 2011; 15: 933-936